Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

QR Code

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes

Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West Birmingham Hospitals NHS Trust, City...

Full description

Saved in:

Bibliographic Details
Main Authors:	Horner F, Lip PL, Mohammed BR, Fusi-Rubiano W, Gokhale E, Mushtaq B, Chavan R
Format:	article
Language:	EN
Published:	Dove Medical Press 2021
Subjects:	amd ranibizumab aflibercept protocols prn treat & extend Ophthalmology RE1-994
Online Access:	https://doaj.org/article/3daaacb669af4205b2d6cba82c97e077
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
by: Amoaku W, et al.
Published: (2018)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
by: Taipale C, et al.
Published: (2018)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
by: Cvetkova NP, et al.
Published: (2016)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
by: Apsangikar P, et al.
Published: (2021)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
by: Horner F, et al.
Published: (2019)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
by: Patel PJ, et al.
Published: (2017)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
by: Dirani A, et al.
Published: (2018)

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
by: Iida T, et al.
Published: (2016)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
by: Kiss S, et al.
Published: (2018)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
by: Narayanan R, et al.
Published: (2016)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
by: Kaya C, et al.
Published: (2019)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
by: Veluswamy B, et al.
Published: (2020)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
by: Canan H, et al.
Published: (2014)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
by: Jumper JM, et al.
Published: (2018)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
by: Hirakata T, et al.
Published: (2016)

Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice
by: Horner F, et al.
Published: (2020)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
by: Varsha Pramil, et al.
Published: (2021)

Immediate sequential bilateral intravitreal injections: an Indian perspective
by: Tripathy K
Published: (2017)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
by: Kinoshita T, et al.
Published: (2021)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
by: Veritti D, et al.
Published: (2021)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
by: Tagami M, et al.
Published: (2017)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
by: Azuma K, et al.
Published: (2018)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
by: Zhuang Cui, et al.
Published: (2021)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
by: Sakanishi Y, et al.
Published: (2017)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
by: Russo A, et al.
Published: (2018)

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
by: Cui C, et al.
Published: (2017)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
by: Elfandi S, et al.
Published: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
by: Mehta H, et al.
Published: (2020)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
by: Spooner K, et al.
Published: (2017)

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
by: Maruyama-Inoue M, et al.
Published: (2019)